Johnson & Johnson $JNJ Holdings Cut by Carnegie Lake Advisors LLC

Key Points

• Carnegie Lake Advisors cut its Johnson & Johnson stake by 36% in the third quarter, selling 5,079 shares and retaining 9,010 shares worth about $2.39 million. Institutional investors overall own 69.55% of the company.
• Johnson & Johnson reported quarterly EPS of $2.59, beating the $2.53 estimate, while revenue rose 5.9% year over year to $25.40 billion. Its Innovative Medicine division’s sales increased 7.7% to $16.76 billion.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $275.92. The company also declared a quarterly dividend of $1.34 per share, equivalent to a 1.9% yield.

Carnegie Lake Advisors LLC trimmed its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 36.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,010 shares of the company's stock after selling 5,079 shares during the period. Johnson & Johnson accounts for 2.1% of Carnegie Lake Advisors LLC's investment portfolio, making the stock its 14th biggest position. Carnegie Lake Advisors LLC's holdings in Johnson & Johnson were worth $2,385,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Elite Wealth Management Inc. bought a new stake in Johnson & Johnson during the third quarter valued at approximately $6,117,000. M Holdings Securities Inc. bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth $8,091,000. Avantax Planning Partners Inc. grew its position in Johnson & Johnson by 1.0% in the third quarter. Avantax Planning Partners Inc. now owns 45,842 shares of the company's stock worth $12,136,000 after acquiring an additional 449 shares in the last quarter. Brighton Jones LLC increased its stake in Johnson & Johnson by 5.4% in the third quarter. Brighton Jones LLC now owns 60,818 shares of the company's stock valued at $16,101,000 after acquiring an additional 3,093 shares during the last quarter. Finally, Candriam S.C.A. raised its position in Johnson & Johnson by 1.3% during the third quarter. Candriam S.C.A. now owns 516,642 shares of the company's stock valued at $137,276,000 after purchasing an additional 6,468 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the business's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Argus set a $300.00 price objective on Johnson & Johnson in a research report on Wednesday, July 29th. Freedom Capital raised Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 16th. Johnson Rice downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Wednesday, October 21st. TD Cowen restated a "buy" rating on shares of Johnson & Johnson in a report on Tuesday, October 20th. Finally, UBS Group set a $270.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $275.92.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for certain adults with recurrent or metastatic head and neck cancer after prior platinum chemotherapy and immunotherapy. J&J says the treatment is the first new option in this setting in a decade; trial data showed a 42% response rate. The approval extends the drug’s use beyond lung cancer and could broaden its commercial opportunity, though the indication is limited and accelerated approval may require confirmatory evidence. FDA approval announcement
• Positive Sentiment: J&J’s Innovative Medicine division grew third-quarter sales 7.7% to $16.76 billion, with established blockbusters and new launches more than offsetting generic competition. Continued growth despite patent-related headwinds supports the business outlook. Innovative Medicine sales report
• Neutral Sentiment: J&J was included in an article highlighting companies with a history of dividend increases and strong balance sheets. This reinforces its income-investor appeal, but the article does not identify a new company-specific dividend announcement. Dividend raisers article
• Negative Sentiment: Pomerantz LLP announced it is investigating potential claims on behalf of J&J investors. The notice does not provide details of the claims, but the investigation could add legal and reputational uncertainty. Investor investigation announcement

Johnson & Johnson Trading Down 0.0%

NYSE JNJ opened at $276.14 on Monday. Johnson & Johnson has a 1-year low of $185.12 and a 1-year high of $282.02. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The stock has a 50-day moving average of $265.91 and a 200-day moving average of $248.30. The firm has a market cap of $664.76 billion, a PE ratio of 41.84, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. Johnson & Johnson's revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period last year, the company earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio is 81.21%.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.